Here's Why You Should Add AURA Stock to Your Portfolio Now

Zacks
在Zacks上打开
Here's Why You Should Add AURA Stock to Your Portfolio Now

Aura Biosciences AURA is focused on developing innovative therapies for patients with ocular cancers. The company’s growth largely depends on belzupacap sarotalocan (bel-sar), its sole investigational candidate designed to destroy tumor cells while activating the body's immune response against cancer. This dual mechanism could offer a new treatment option for patients with ocular cancers, particularly those who need effective tumor control while preserving vision.

Aura’s Bel-sar is currently being evaluated in the global phase III CoMpass study for the treatment of early choroidal melanoma, a type of eye cancer that originates in the choroid, the layer of blood vessels beneath the retina. The disease carries a significant risk of spreading to other parts of the body. Currently, no FDA-approved drug therapies are available for this indication.

During the third quarter of 2026, patient enrollment and dosing in the CoMpass study were completed, with top-line data expected in the second half of 2027. Positive data could support a potential biologics license application filing for the drug. If successful, bel-sar could become the first FDA-approved frontline vision-preserving drug therapy for early choroidal melanoma.           

Year to date, AURA shares have risen 39.6% compared with the industry’s 11.3% growth.

Zacks Investment Research
Image Source: Zacks Investment Research

Aura's Bel-sar Potential Expands Beyond Choroidal Melanoma

Beyond early choroidal melanoma, Aura is exploring bel-sar in other ocular cancers, creating additional opportunities to expand its pipeline.The company is advancing bel-sar in choroidal metastases, which occur when cancer spreads to the choroid from other parts of the body. The program could extend the candidate's potential use beyond primary ocular cancers. Aura is evaluating bel-sar in cancers of the ocular surface. These programs remain in early clinical development but could provide additional growth opportunities if future studies demonstrate meaningful clinical benefits. The company expects to provide updates on both programs in the first quarter of 2027.

Notably, its expected cash runway into the first half of 2029 provides financial support for the company's key development plans and reduces near-term financing pressure.

Aura Biosciences, Inc. Price and Consensus

Aura Biosciences, Inc. Price and Consensus

Aura Biosciences, Inc. price-consensus-chart | Aura Biosciences, Inc. Quote

AURA’s Zacks Rank & Estimates

Aura currently has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Over the past 30 days, estimates for Aura’s 2026 loss per share have narrowed from $1.61 to $1.50 and the same for 2027 have narrowed from $1.39 to $1.19.

Other Stocks to Consider

Some other top-ranked stocks in the biotech sector are Amneal Pharmaceuticals AMRX, currently sporting a Zacks Rank #1, AC Immune ACIU and Adaptive Biotechnologies ADPT, carrying a Zacks Rank #2 each.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.03 to $1.06 for 2026. Over the same period, estimates for 2027 earnings per share have risen from $1.16 to $1.21. AMRX’s shares have climbed 72.3% year to date.

Amneal Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.21%.

Over the past 30 days, loss per share estimates for AC Immune have narrowed from 60 cents to 54 cents for 2026. Over the same period, estimates for 2027 earnings per share have increased from 17 cents to 43 cents. ACIU’s shares have plunged 28% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with an average surprise of 37.79%.

Over the past 30 days, loss per share estimates for Adaptive Biotechnologies have narrowed from 55 cents to 44 cents for 2026. Over the same period, estimates for 2027 loss per share have improved from 17 cents to 8 cents. ADPT’s shares have surged 84.3% year to date.

Adaptive Biotechnologies’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 53.62%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Aura Biosciences, Inc. (AURA): Free Stock Analysis Report
 
Adaptive Biotechnologies Corporation (ADPT): Free Stock Analysis Report
 
AC Immune (ACIU): Free Stock Analysis Report
 
AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research